Issue 16, 2018

A hypoxia-specific and mitochondria-targeted anticancer theranostic agent with high selectivity for cancer cells

Abstract

Herein, a novel soluble mitochondria-targeted theranostic compound, HMX-1, was presented, which was selectively activated under hypoxia with excellent mitochondria-targeting ability at the cellular level, accompanied by a dramatic increase in the fluorescence intensity. Moreover, its anti-cancer efficiency was certified both in vitro and in vivo.

Graphical abstract: A hypoxia-specific and mitochondria-targeted anticancer theranostic agent with high selectivity for cancer cells

Associated articles

Supplementary files

Article information

Article type
Communication
Submitted
16 Mar 2018
Accepted
03 Apr 2018
First published
03 Apr 2018

J. Mater. Chem. B, 2018,6, 2413-2416

A hypoxia-specific and mitochondria-targeted anticancer theranostic agent with high selectivity for cancer cells

M. Hu, C. Yang, Y. Luo, F. Chen, F. Yang, S. Yang, H. Chen, Z. Cheng, K. Li and Y. Xie, J. Mater. Chem. B, 2018, 6, 2413 DOI: 10.1039/C8TB00546J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements